

MED28 RABBIT PAB

Cat.#: S217939

Product Name: Anti-MED28 Rabbit Polyclonal Antibody

Synonyms: EGI; magicin; 1500003D12Rik

UNIPROT ID: Q9H204 (Gene Accession - BC011936)

Background: Med28 (mediator complex subunit 28), also known as EGI (endothelial-derived protein 1), magicin (merlin and Grb2-interacting cytoskeletal protein) or tumor angiogenesis marker EG-1, is a 178 amino acid subunit of the Mediator complex that localizes to both nucleus and cytoplasm.

Immunogen: Full length fusion protein

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 25-100;WB: 500-2000;ELISA: 2000-5000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Epigenetics and Nuclear Signaling


Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 217939(MED28 Antibody) at a dilution of 1/30(Cytoplasm or Nucleus).




In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the fusion protein and then with 217939(Anti-MED28 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 217939(Anti-MED28 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D223403(Anti-MED28 Antibody) at dilution 1/30.



Gel: 12%SDS-PAGE, Lysate: 40 µg;
Lane: Human placenta tissue;
Primary antibody: 217939(MED28 Antibody) at dilution 1/400;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 30 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
